EdwardChanMD
Pediatric Hematology & Oncology • Thousand Oaks, CAClinical research medical director, Amgen
Dr. Chan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
One Amgen Center Drive
Bldg 27, 3E
Thousand Oaks, CA 91320- Is this information wrong?
Education & Training
Cincinnati Children's Hospital Medical CenterFellowship, Pediatric Hematology/Oncology, 2000 - 2003
University at BuffaloResidency, Pediatrics, 1997 - 2000- Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1997
Certifications & Licensure
NY State Medical License 2005 - 2024- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
- Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma Start of enrollment: 2015 Feb 03
- Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma Start of enrollment: 2014 Dec 08
- Join now to see all
Publications & Presentations
PubMed
- 51 citationsRandomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.Jason A Chesney, Antoni Ribas, Georgina V Long, John M Kirkwood, Reinhard Dummer, Igor Puzanov, Christoph Hoeller, Thomas F Gajewski, Ralf Gutzmer, Piotr Rutkowski, Le...> ;Journal of Clinical Oncology. 2023 Jan 20
- 2 citationsA phosphoarray platform is capable of personalizing kinase inhibitor therapy in head and neck cancers.Konrad Klinghammer, James Keller, Jonathan George, Jens Hoffmann, Edward L. Chan, Michael J. Hayman> ;International Journal of Cancer. 2018 Jan 1
- 7 citationsA Novel EGFR Extracellular Domain Mutant, EGFRΔ768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma.James Keller, Anjaruwee S. Nimnual, Mathew S. Varghese, Kristen A. VanHeyst, Michael J. Hayman, Edward L. Chan> ;Molecular Cancer Research. 2016 Aug 1
- Join now to see all
Grant Support
- Validating the prognostic value of EGFR768 in neuroblastomaNational Cancer Institute2014–2016
- Ron as an adjunct biomarker for EGFR expressing head and neck cancersAmerican Cancer Society2009–2015
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
